Emerging Therapies for Colon Cancer: A Review of PD-1/PD-L1-Targeted Antibodies

Strategic Insights -

Researchers at the University of Lodz in Poland have published a comprehensive review of the therapeutic potential of emerging PD-1/PD-L1-targeted antibodies in colorectal cancer. The study highlights the current treatment options, including pembrolizumab, nivolumab, and dostarlimab, and explores the challenges and complexities of combination strategies. The researchers aim to provide insights into the evolving landscape of PD-1/PD-L1-targeted therapies in CRC and their potential to improve patient outcomes.

Key Takeaways:

  • The PD-1/PD-L1 pathway has emerged as a critical target in colorectal cancer immunotherapy, with significant clinical efficacy observed in microsatellite instability-high (MSI-H) and mismatch repair-deficient (dMMR) tumors.
  • Pembrolizumab, nivolumab, and dostarlimab have demonstrated significant clinical efficacy in CRC, particularly in MSI-H and dMMR tumors.
  • A growing number of additional PD-1/PD-L1 inhibitors, including AMP-224, atezolizumab, avelumab, camrelizumab, durvalumab, envafolimab, sintilimab, spartalizumab, tislelizumab, and toripalimab, are currently under investigation, offering new possibilities for expanding treatment options.
  • The review evaluates the therapeutic potential of these emerging agents, assessing their clinical development, mechanisms of action, and potential advantages over established therapies.
  • The study highlights key challenges, including primary and acquired resistance, limited efficacy in microsatellite-stable (MSS) CRC, and the complexities of combination strategies aimed at enhancing immunotherapeutic responses.

Statistics:

  • 13 new PD-1/PD-L1 inhibitors are in various stages of clinical development for colorectal cancer, including AMP-224, atezolizumab, avelumab, camrelizumab, durvalumab, envafolimab, sintilimab, spartalizumab, tislelizumab, and toripalimab.
  • The review focuses on the potential advantages and limitations of these emerging agents compared to established therapies like pembrolizumab, nivolumab, and dostarlimab.

Sources:

  • Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review. Molecules, 2025,30(13):2686. (Molecules - http://www.mdpi.com/journal/molecules).
  • University of Lodz, Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Banacha Street 12, 16, 90-237 Lodz, Poland.